These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 19367251)

  • 1. Managing trastuzumab-resistant breast cancer.
    Krop I
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
    [No Abstract]   [Full Text] [Related]  

  • 2. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?
    Araki K; Pegram M
    Breast Cancer Res Treat; 2011 Jun; 127(2):589-90. PubMed ID: 19834800
    [No Abstract]   [Full Text] [Related]  

  • 5. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 6. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 7. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Herceptin (trastuzumab)].
    Yamashiro H; Toi M
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil elastase predicts trastuzumab responsiveness in metastatic breast cancer.
    Yamashita J; Akizuki M; Jotsuka T; Harao M; Nakano S
    Breast J; 2006; 12(3):288. PubMed ID: 16684339
    [No Abstract]   [Full Text] [Related]  

  • 11. HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients.
    Altundag O; Altundag K; Ozcakar B; Silay YS
    Lung Cancer; 2005 Aug; 49(2):279-80. PubMed ID: 16022924
    [No Abstract]   [Full Text] [Related]  

  • 12. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

  • 13. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P; Guarneri V; Bengala C
    Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.
    Spector N
    Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S94-9. PubMed ID: 18777948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab.
    Perez EA; Palmieri FM; Brock SM
    Cancer Treat Res; 2009; 151():181-96. PubMed ID: 19593513
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab in the treatment of breast cancer.
    Hortobagyi GN
    N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
    [No Abstract]   [Full Text] [Related]  

  • 19. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab faces trials, clinical and otherwise.
    Tuma RS
    J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.